Epigenetics: Applications for Pharmaceuticals and Diagnostics

Oct. 4, 2012 - PRLog -- ReportReserve announces the inclusion of its new report published by Global Kalorama Information.
"Mabs" and molecular tests are among the growth industries of pharmaceuticals and diagnostics, but they may have competition long-term from an unexpected source. Epigenomics is a potential game-changer in the clinical therapeutics market and significant in testing as well. It refers to technologies involving changes in genetic material that find their origins in causes other than base pairs alterations in the DNA of the host.  Examples of such changes include DNA methylation and histone acetylation, both of which have been known for many years to cause changes in gene expression. This report Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics describes the progress that has been made in our understanding of the basic science of epigenomics and considers the practical accomplishments being reported by the private sector.


Epigenomics constitutes a challenge to the long held paradigm of DNA base pair sequences as the prime determinant of the phenotype. Because of this profound intellectual shift, a vast new area of biological investigation is rapidly unfolding. This presents significant opportunities for understanding disease processes and developing the means of combating them.

Epigenomic Mechanisms Discussed in the report include:

   DNA methylation
   Histone Acetylation
   Histone Phosphorylation
   Methylation
   Sumoylation
   Histone “chaperones”
   MicroRNAs (miRNAs)

The examination of many diseases in a completely new light means there exist a wealth of opportunities to develop new diagnostic and therapeutic approaches. At the same time it means that outdated concepts will have to be revised.  This report looks at the science behind epigenomics and deals with opportunities for product development based on epigenetic technologies and the outlook for the future in this exciting area of pharmaceutical technologies.  In doing so, the report provides:

   Discussion of the Basic Science and Mechanisms Behind Epigenomics
   Activities of Top Companies in the Market
   Interviews with Researchers and Private Sector Leaders
   Market Estimates for Current Epigenomic Drugs and Forecast to 2017
   Market Estimates for Current Epigenomic Diagnostics and Comparison to Next Gen Cancer Diagnostics Market
   Analyst Conclusions Regarding the Future Market for Epigenomics
   Key Healthcare Segments Impacted by Epigenomics
   Examples of Clinically Relevant Epigenetic Biomarkers
   Currently Approved Epigenomic Drugs
   Epigenetic Drivers of Disease
   Pharmaceutical R&D: A Need for Better Returns
   Look at Applications in Alzheimer’s Disease, Mental Illness, Auto-Immune Diseases, Autism and Cardiovascular Disease



For further information please visit http://www.reportreserve.com/report/epigenetics-applicati...